Compare Mesoblast Limited (MESO) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs State Street Technology Select Sector SPDR ETF — how do they compare? Mesoblast Limited trades at $16.33 (market cap $2.17B), while State Street Technology Select Sector SPDR ETF trades at $180.64. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | XLK | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $20.96 | $198.21 |
52-Week Low | $12.88 | $127.49 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
XLK trades at $175.71 with minimal daily movement (+0.07%), showing technical bearish signals while maintaining strong year-to-date performance of 33%. The ETF's technical indicators show selling pressure with bearish moving averages, though oscillators remain neutral. Recent news highlights XLK as the top-performing sector SPDR in 2026, driven by technology sector strength and institutional inflows.
Outlook remains positive given technology sector momentum and strong earnings expectations, though concentration risk and technical weakness warrant monitoring. The ETF benefits from sector leadership but faces headwinds from potential Fed policy shifts and market volatility. Current levels near pivot point resistance at $176 suggest near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
